{"transactions":[{"id":1358,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-02T23:05:02.000Z","date":"2026-08-31","kind":"sale","planned":false,"acquired":false,"shares":9683,"price":2.7531,"value":26658.2673,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $2.7531, and the range of prices were between $2.70 and $2.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided"}],"balance_after":258688,"source":{"system":"sec-edgar","filing":"0001493152-26-041283","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1937482/000149315226041283/ownership.xml","form_type":"4"}},{"id":697019,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T00:20:11.000Z","date":"2026-08-04","kind":"sale","planned":false,"acquired":false,"shares":653,"price":2.9434,"value":1922.0402,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $2.9434, and the range of prices were between $2.93 and $2.975. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":268371,"source":{"system":"sec-edgar","filing":"0001493152-26-036077","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226036077/ownership.xml","form_type":"4"}},{"id":731832,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-18T23:05:12.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":119318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter."}],"balance_after":269024,"source":{"system":"sec-edgar","filing":"0001493152-26-029414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226029414/ownership.xml","form_type":"4"}},{"id":782181,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-13T00:30:06.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":605,"price":2.9726,"value":1798.423,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $2.9726, and the range of prices were between $2.95 and $3.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":149706,"source":{"system":"sec-edgar","filing":"0001493152-26-022567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226022567/ownership.xml","form_type":"4"}},{"id":827243,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2026-03-26T21:00:21.000Z","date":"2026-03-24","kind":"sale","planned":false,"acquired":false,"shares":906,"price":2.42,"value":2192.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."}],"balance_after":144938,"source":{"system":"sec-edgar","filing":"0001493152-26-012970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226012970/ownership.xml","form_type":"4"}},{"id":972498,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2025-12-12T01:50:02.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":973,"price":5.3694,"value":5224.4262,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025."}],"balance_after":145844,"source":{"system":"sec-edgar","filing":"0001493152-25-027338","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000149315225027338/ownership.xml","form_type":"4"}},{"id":972497,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2025-12-12T01:50:02.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":3219,"price":3.3574,"value":10807.4706,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025."}],"balance_after":146817,"source":{"system":"sec-edgar","filing":"0001493152-25-027338","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000149315225027338/ownership.xml","form_type":"4"}},{"id":1049369,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-03T20:15:33.000Z","date":"2025-09-01","kind":"grant","planned":false,"acquired":true,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":65000,"derivative":{"exercise_price":3.33,"expiration_date":"2033-09-10","underlying":"Common stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001641172-25-026397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225026397/ownership.xml","form_type":"4"}},{"id":1049368,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-03T20:15:33.000Z","date":"2025-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":22.4,"expiration_date":"2033-09-10","underlying":"Common stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001641172-25-026397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225026397/ownership.xml","form_type":"4"}},{"id":1049367,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-03T20:15:33.000Z","date":"2025-09-01","kind":"grant","planned":false,"acquired":true,"shares":207652,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested."}],"balance_after":207652,"derivative":{"exercise_price":3.33,"expiration_date":"2029-09-20","underlying":"Common stock","underlying_shares":207652},"source":{"system":"sec-edgar","filing":"0001641172-25-026397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225026397/ownership.xml","form_type":"4"}},{"id":1049366,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-03T20:15:33.000Z","date":"2025-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":207652,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":6,"expiration_date":"2029-09-20","underlying":"Common stock","underlying_shares":207652},"source":{"system":"sec-edgar","filing":"0001641172-25-026397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225026397/ownership.xml","form_type":"4"}},{"id":1052714,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T20:30:52.000Z","date":"2025-08-27","kind":"grant","planned":false,"acquired":true,"shares":134520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":134520,"derivative":{"exercise_price":3.64,"expiration_date":"2035-08-26","underlying":"Common stock","underlying_shares":134520},"source":{"system":"sec-edgar","filing":"0001641172-25-026001","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225026001/ownership.xml","form_type":"4"}},{"id":1052713,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Clinical Development"}}],"security":"Common Stock","published_at":"2025-08-29T20:30:52.000Z","date":"2025-08-27","kind":"grant","planned":false,"acquired":true,"shares":101480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 916 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":150036,"source":{"system":"sec-edgar","filing":"0001641172-25-026001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000164117225026001/ownership.xml","form_type":"4"}},{"id":1150639,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2025-05-13T21:05:37.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":5579,"price":2.92,"value":16290.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."}],"balance_after":47640,"source":{"system":"sec-edgar","filing":"0001415889-25-012807","document":"form4-05132025_050533.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588925012807/form4-05132025_050533.xml","form_type":"4"}},{"id":1169594,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2025-04-17T20:56:26.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":13350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025."}],"balance_after":53219,"source":{"system":"sec-edgar","filing":"0001415889-25-010879","document":"form4-04172025_080423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588925010879/form4-04172025_080423.xml","form_type":"4"}},{"id":1323959,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-21T01:46:33.000Z","date":"2024-12-18","kind":"grant","planned":false,"acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares vest on August 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":39000,"derivative":{"exercise_price":2.29,"expiration_date":"2034-12-17","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001415889-24-030005","document":"form4-12212024_011230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588924030005/form4-12212024_011230.xml","form_type":"4"}},{"id":1323958,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2024-12-21T01:46:33.000Z","date":"2024-12-18","kind":"grant","planned":false,"acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs vest on August 1, 2025, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter."}],"balance_after":39869,"source":{"system":"sec-edgar","filing":"0001415889-24-030005","document":"form4-12212024_011230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588924030005/form4-12212024_011230.xml","form_type":"4"}},{"id":1458220,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2024-07-08T20:30:13.000Z","date":"2024-06-24","kind":"sale","planned":false,"acquired":false,"shares":6849,"price":2.12,"value":14519.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of RSUs."}],"balance_after":10869,"source":{"system":"sec-edgar","filing":"0001415889-24-019343","document":"form4-07082024_040709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588924019343/form4-07082024_040709.xml","form_type":"4"}},{"id":1458219,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2024-07-08T20:30:13.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":11557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents RSUs that are fully vested as of March 14, 2024."}],"balance_after":17718,"source":{"system":"sec-edgar","filing":"0001415889-24-019343","document":"form4-07082024_040709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588924019343/form4-07082024_040709.xml","form_type":"4"}},{"id":1458218,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2024-07-08T20:30:13.000Z","date":"2024-02-19","kind":"grant","planned":false,"acquired":true,"shares":3661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024."}],"balance_after":6161,"source":{"system":"sec-edgar","filing":"0001415889-24-019343","document":"form4-07082024_040709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588924019343/form4-07082024_040709.xml","form_type":"4"}},{"id":1486431,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2024-06-08T01:40:14.000Z","date":"2024-05-29","kind":"purchase","planned":false,"acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 15, 2023.  The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock.  The combined price of each share of common stock offered together with one warrant was $4.00."}],"balance_after":2500,"derivative":{"exercise_price":5.25,"exercise_date":"2024-05-29","expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-24-016101","document":"form4-06072024_090610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588924016101/form4-06072024_090610.xml","form_type":"4"}},{"id":1486430,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2024-06-08T01:40:14.000Z","date":"2024-05-29","kind":"purchase","planned":false,"acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 15, 2023.  The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock.  The combined price of each share of common stock offered together with one warrant was $4.00."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001415889-24-016101","document":"form4-06072024_090610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000141588924016101/form4-06072024_090610.xml","form_type":"4"}},{"id":1706882,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-12-18T21:15:20.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":5803,"price":14.1763,"value":82265.0689,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.1763, and the range of prices were between $13.80 and $14.535. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-058954","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123058954/doc4.xml","form_type":"4"}},{"id":1706881,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-12-18T21:15:20.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":26732,"price":12.9401,"value":345914.7532,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $12.9401, and the range of prices were between $12.69 and $13.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":5803,"source":{"system":"sec-edgar","filing":"0001209191-23-058954","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123058954/doc4.xml","form_type":"4"}},{"id":1717661,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-12-08T22:57:37.000Z","date":"2023-12-07","kind":"sale","planned":false,"acquired":false,"shares":36800,"price":11.8477,"value":435995.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $11.8477, and the range of prices were between $11.51 and $12.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":32535,"source":{"system":"sec-edgar","filing":"0001209191-23-057975","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123057975/doc4.xml","form_type":"4"}},{"id":1730973,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-11-22T21:15:09.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":18665,"price":10.2628,"value":191555.162,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $10.2628, and the range of prices were between $9.91 and $10.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":69335,"source":{"system":"sec-edgar","filing":"0001209191-23-056455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123056455/doc4.xml","form_type":"4"}},{"id":1732434,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-11-21T21:15:27.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":14594,"price":11.2554,"value":164261.3076,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.2554, and the range of prices were between $11.00 and $11.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":88000,"source":{"system":"sec-edgar","filing":"0001209191-23-056237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123056237/doc4.xml","form_type":"4"}},{"id":1732433,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-11-21T21:15:27.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":3541,"price":13.0386,"value":46169.6826,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $13.0386, and the range of prices were between $13.00 and $13.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":102594,"source":{"system":"sec-edgar","filing":"0001209191-23-056237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123056237/doc4.xml","form_type":"4"}},{"id":1755164,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-25T20:15:26.000Z","date":"2023-10-24","kind":"exercise","planned":false,"acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":207653,"derivative":{"exercise_price":6,"expiration_date":"2029-09-20","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001209191-23-053554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123053554/doc4.xml","form_type":"4"}},{"id":1755163,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-10-25T20:15:26.000Z","date":"2023-10-24","kind":"sale","planned":false,"acquired":false,"shares":5200,"price":19.106,"value":99351.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $19.106, and the range of prices were between $19.00 and $19.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":106135,"source":{"system":"sec-edgar","filing":"0001209191-23-053554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123053554/doc4.xml","form_type":"4"}},{"id":1755162,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-10-25T20:15:26.000Z","date":"2023-10-24","kind":"exercise","planned":false,"acquired":true,"shares":5200,"price":6,"value":31200.0,"ownership":{"direct":true},"balance_after":111335,"source":{"system":"sec-edgar","filing":"0001209191-23-053554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123053554/doc4.xml","form_type":"4"}},{"id":1761739,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-11T20:10:07.000Z","date":"2023-10-10","kind":"exercise","planned":false,"acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":212853,"derivative":{"exercise_price":6,"expiration_date":"2029-09-20","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001209191-23-052621","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123052621/doc4.xml","form_type":"4"}},{"id":1761738,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-10-11T20:10:07.000Z","date":"2023-10-10","kind":"sale","planned":false,"acquired":false,"shares":400,"price":22.906,"value":9162.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $22.906, and the range of prices were between $22.82 and $22.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":106135,"source":{"system":"sec-edgar","filing":"0001209191-23-052621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123052621/doc4.xml","form_type":"4"}},{"id":1761737,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-10-11T20:10:07.000Z","date":"2023-10-10","kind":"sale","planned":false,"acquired":false,"shares":4800,"price":21.9374,"value":105299.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $21.9374, and the range of prices were between $21.54 and $22.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":106535,"source":{"system":"sec-edgar","filing":"0001209191-23-052621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123052621/doc4.xml","form_type":"4"}},{"id":1761736,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-10-11T20:10:07.000Z","date":"2023-10-10","kind":"exercise","planned":false,"acquired":true,"shares":5200,"price":6,"value":31200.0,"ownership":{"direct":true},"balance_after":111335,"source":{"system":"sec-edgar","filing":"0001209191-23-052621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123052621/doc4.xml","form_type":"4"}},{"id":1772542,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-27T20:10:09.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately exercisable."}],"balance_after":218053,"derivative":{"exercise_price":6,"expiration_date":"2029-09-20","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001209191-23-050643","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050643/doc4.xml","form_type":"4"}},{"id":1772541,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-27T20:10:09.000Z","date":"2023-09-26","kind":"sale","planned":false,"acquired":false,"shares":2203,"price":24.4623,"value":53890.4469,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $24.4623, and the range of prices were between $24.24 and $24.755. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":106135,"source":{"system":"sec-edgar","filing":"0001209191-23-050643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050643/doc4.xml","form_type":"4"}},{"id":1772540,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-27T20:10:09.000Z","date":"2023-09-26","kind":"sale","planned":false,"acquired":false,"shares":1114,"price":23.5145,"value":26195.153,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $23.5145, and the range of prices were between $23.16 and $24.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":108338,"source":{"system":"sec-edgar","filing":"0001209191-23-050643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050643/doc4.xml","form_type":"4"}},{"id":1772539,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-27T20:10:09.000Z","date":"2023-09-26","kind":"sale","planned":false,"acquired":false,"shares":1883,"price":22.5397,"value":42442.2551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $22.5397, and the range of prices were between $22.13 and $23.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":109452,"source":{"system":"sec-edgar","filing":"0001209191-23-050643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050643/doc4.xml","form_type":"4"}},{"id":1772538,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-27T20:10:09.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":true,"shares":5200,"price":6,"value":31200.0,"ownership":{"direct":true},"balance_after":111335,"source":{"system":"sec-edgar","filing":"0001209191-23-050643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050643/doc4.xml","form_type":"4"}},{"id":1775316,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-21T20:35:11.000Z","date":"2023-09-20","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":223253,"derivative":{"exercise_price":6,"expiration_date":"2029-09-20","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-23-050282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050282/doc4.xml","form_type":"4"}},{"id":1775315,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-21T20:35:11.000Z","date":"2023-09-20","kind":"sale","planned":false,"acquired":false,"shares":6000,"price":27.9643,"value":167785.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $27.9643, and the range of prices were between $27.95 and $28.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":106135,"source":{"system":"sec-edgar","filing":"0001209191-23-050282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050282/doc4.xml","form_type":"4"}},{"id":1775314,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-21T20:35:11.000Z","date":"2023-09-20","kind":"exercise","planned":false,"acquired":true,"shares":6000,"price":6,"value":36000.0,"ownership":{"direct":true},"balance_after":112135,"source":{"system":"sec-edgar","filing":"0001209191-23-050282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123050282/doc4.xml","form_type":"4"}},{"id":1778729,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-19T00:13:33.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":false,"shares":10400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":229253,"derivative":{"exercise_price":6,"expiration_date":"2029-09-20","underlying":"Common Stock","underlying_shares":10400},"source":{"system":"sec-edgar","filing":"0001209191-23-049841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123049841/doc4.xml","form_type":"4"}},{"id":1778728,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-19T00:13:33.000Z","date":"2023-09-15","kind":"sale","planned":false,"acquired":false,"shares":4675,"price":22.2913,"value":104211.8275,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $22.2913, and the range of prices were between $22.02 and $22.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":106135,"source":{"system":"sec-edgar","filing":"0001209191-23-049841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123049841/doc4.xml","form_type":"4"}},{"id":1778727,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-19T00:13:33.000Z","date":"2023-09-15","kind":"sale","planned":false,"acquired":false,"shares":5725,"price":21.5578,"value":123418.405,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $21.5578, and the range of prices were between $21.01 and $21.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":110810,"source":{"system":"sec-edgar","filing":"0001209191-23-049841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123049841/doc4.xml","form_type":"4"}},{"id":1778726,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-19T00:13:33.000Z","date":"2023-09-15","kind":"exercise","planned":false,"acquired":true,"shares":10400,"price":6,"value":62400.0,"ownership":{"direct":true},"balance_after":116535,"source":{"system":"sec-edgar","filing":"0001209191-23-049841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123049841/doc4.xml","form_type":"4"}},{"id":1779958,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-09-16T00:06:13.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":29800,"price":21.1385,"value":629927.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $21.1385, and the range of prices were between $21.00 and $21.58. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":106135,"source":{"system":"sec-edgar","filing":"0001209191-23-049673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123049673/doc4.xml","form_type":"4"}},{"id":1782795,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-12T20:24:29.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":65000,"derivative":{"exercise_price":22.4,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-049101","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123049101/doc4.xml","form_type":"4"}},{"id":1792898,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-08-30T23:22:03.000Z","date":"2023-08-30","kind":"sale","planned":false,"acquired":false,"shares":19800,"price":24.7,"value":489060.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $24.70, and the range of prices were between $24.70 and $24.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":135935,"source":{"system":"sec-edgar","filing":"0001209191-23-047784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123047784/doc4.xml","form_type":"4"}},{"id":1799540,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-08-22T20:14:57.000Z","date":"2023-08-18","kind":"sale","planned":false,"acquired":false,"shares":3265,"price":23.73,"value":77478.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":155735,"source":{"system":"sec-edgar","filing":"0001209191-23-046879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123046879/doc4.xml","form_type":"4"}},{"id":1908081,"issuer":{"id":1116,"kind":"organization","name":"GENELUX Corp","symbol":"GNLX"},"owners":[{"id":1119,"kind":"person","name":"Yu Yong","position":1,"cik":"0001937482","reported_name":"Yu Tony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Clinical Trial Operations"}}],"security":"Common Stock","published_at":"2023-05-02T20:22:52.000Z","date":"2023-02-17","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the Issuer's 2022 Equity Incentive Plan.  Each RSU represents the contingent right to receive one share of common stock upon vesting.  The RSUs will be fully vested on July 25, 2023."}],"balance_after":159000,"source":{"system":"sec-edgar","filing":"0001209191-23-026488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1231457/000120919123026488/doc4.xml","form_type":"4"}}]}